- Preclinical irreversible small molecule concern, Biomea Fusion, Inc., has lost 40% of its share value since its April 2021 IPO, suffering from a lack of news rather than bad.
- The company’s covalent bonding compounds offer advantages over reversible oncology therapeutics, which could lead to higher efficacy, as well as better safety and tolerability profiles.
- With its first IND expected to be filed soon and recent beneficial owner buying, this busted IPO merited a deeper dive.
- A full investment analysis follows in the paragraphs below.
For further details see:
Biomea Fusion: Patience Warranted